John Hancock Funds has changed the names of two of its funds.
As of Oct. 1, the John Hancock Sovereign Bond Fund is the John Hancock Bond Fund and the John Hancock Global Rx Fund is the John Hancock Global Health Sciences Fund.
The funds' investment objectives remain unchanged; the new names are meant to clarify their investment strategies, the Boston-based company said.
The Bond Fund invests mainly in high-grade corporate and government bonds, and the Health Sciences Fund invests in foreign and U.S. health-care companies.
In other news, the company has named James V. Bowhers president of the sales and marketing arm of the fund complex. Mr. Bowhers, an executive who oversees several areas of the company, is now in charge of nonbank brokerages.
Robert G. Freedman, the company's chief investment officer, has taken on the new role of managing principal of Hancock's high-net-worth management business.